Skip to content

Effect of Ayurvedic treatment in the management of delayed menses

Efficacy of Erandamuladi Niruha Basti and Vidari Shatapushpa Churna in Management of Kshina Artavadusti W.S.R. to Premature Ovarian Insufficiency: A Single Arm Open Labelled Clinical Trial - NIL

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2024/05/066863
Enrollment
20
Registered
2024-05-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-11-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N914- Secondary oligomenorrhea

Interventions

None listed

Sponsors

Institute of Teaching and Research in Ayurveda
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Age group greater than or equal to 18 years and less than or equal to 40 years Married and unmarried females Patients having 1 or more symptoms below for at least 4 consecutive months Delayed menses (cycle of more than 35 days) Absent menses (no menstrual bleeding for at least 4 months) Scanty menses (duration of menstrual flow 2 days or less ) Patients suitable for Basti procedure

Exclusion criteria

Exclusion criteria: Pregnancy Lactational amenorrhoea Congenital defect in genital tract Polycystic Ovarian Disease Primary amenorrhoea Known case of active malignant disease Patients having active inflammatory disease. e.g. Acute PID, STD like HIV, VDRL, HBsAg, HCV and TORCH positive. Chronic systemic disease like uncontrolled Hypertension (Systolic BP more than 160mmHgandDiastolic BP more than 100mmHg), uncontrolled DM (RBS more than 160mg/dl) Patients not willing to participate in the study.

Design outcomes

Primary

MeasureTime frame
To attain normal cyclic menstrual bleeding i.e menses with cyclic interval of 21-35 days with a meanof 28 days andduration of the menstrual flow being 4-5 days.Timepoint: 4 months

Secondary

MeasureTime frame
Improvement in Antral Follicle Count (AFC), values of Follicle Stimulating Hormone (FSH) and Estradiol(E2). Releif in associated menopausal symptoms as per Modified Kupperman Index.Timepoint: 4 months

Countries

India

Contacts

Public ContactDr Hetal Baraiya

Institute of Teaching and Research in Ayurveda, Jamnagar

hpbaria@itra.edu.in9925954927

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026